Alzheimer’s disease and CBD
Alzheimer’s disease and CBD
Alzheimer’s disease

Alzheimer’s disease is the most common neurodegenerative disorder and, unfortunately, is poised to become more common as the global population ages. There are currently 30 million people [1] with Alzheimer’s, but researchers project that it could reach 115 by 2050 [2]. The disease is characterized by, among other things [3][4][5], neuronal loss, particularly in the neocortex and hippocampus regions of the brain, eventually leading to memory loss and a decline in cognitive function [1]. Alzheimer’s has two categories, sporadic (95% of the cases) and familial (5% of the cases) [6]. These types seem to be associated with different genes, but there is no distinction between the two regarding symptoms. The only difference is that patients with the familial type tend to develop it earlier. Overall, the cause and mechanisms of Alzheimer’s are still far from fully understood, despite existing hypotheses [7]-[11]. The approved therapies for Alzheimer’s do not stop or reverse the progression of the disease and are only used for the management of symptoms. These include cholinesterase inhibitors, memantine, and NMDA receptor antagonists. However, these treatments only have limited effects [12]. The thinking is that a drug that acts on a single pathway or targets a specific molecule will not influence the complex way the disease unfolds. A multifaceted treatment approach might address a number of issues linked to Alzheimer’s [13][14]. 

CBD and Alzheimer’s disease

The endocannabinoid system is involved in the progression of Alzheimer’s due to its role in oxidative stress, glial cell activation, and clearance of macromolecules [15][16][17]. As CBD modulates the ECS, researchers have tested it in a variety of in vitro [18]-[24] and in vivo [25]-[28] preclinical models, with promising results. Because of these results, research is now shifting to clinical studies [29].

Dosing recommendations for Alzheimer’s patients

Is CBD safe? 

Yes. CBD is considered safe for Alzheimer’s.

What is the recommended daily dose? 

Start with 1 mg/kg/day and titrate to effect - possibly as high as

20 mg/kg/day. Read General recommendations!

Should I take it before or after a meal? 

CBD should be taken during, or after a meal. 

How many times a day should I take CBD? 

Take your dose twice
a day. Half of it in the morning and the other half in the evening. 

Are there any known drug interactions? 

Some. Read Side effects for more information.


1. Calvo-Rodriguez M, Kharitonova EK and Bacskai BJ: Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease. Cells 9: 2020. 

2. Wisniewski T and Goñi F: Immunotherapy for Alzheimer's disease. Biochemical pharmacology 88: 499-507, 2014. 

3. Imbimbo BP, Lombard J and Pomara N: Pathophysiology of Alzheimer's disease. Neuroimaging clinics of North America 15: 727-753, ix, 2005. 

4. Kumar A, Singh A and Ekavali: A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological Reports 67: 195-203, 2015. 

5. Selkoe DJ: Alzheimer's disease. Cold Spring Harbor perspectives in biology 3: 2011. 

6. Götz J and Ittner LM: Animal models of Alzheimer's disease and frontotemporal dementia. Nature reviews Neuroscience 9: 532-544, 2008. 


8. Frost B, Jacks RL and Diamond MI: Propagation of Tau Misfolding from the Outside to the Inside of a Cell. Journal of Biological Chemistry 284: 12845-12852, 2009. 

9. Hardy JA and Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science (New York, NY) 256: 184-185, 1992. 

10. McGeer PL and Rogers J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42: 447-449, 1992. 

11. Tarasoff-Conway JM, Carare RO, Osorio RS, et al: Clearance systems in the brain-implications for Alzheimer disease. Nature reviews Neurology 11: 457-470, 2015. 

12. Salomone S, Caraci F, Leggio GM, Fedotova J and Drago F: New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British journal of clinical pharmacology 73: 504-517, 2012. 

13. Bedse G, Romano A, Lavecchia AM, Cassano T and Gaetani S: The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. Journal of Alzheimer's disease : JAD 43: 1115-1136, 2015. 

14. Van der Schyf CJ and Geldenhuys WJ: Multimodal drugs and their future for Alzheimer's and Parkinson's disease. In: International Review of Neurobiology. Vol 100. Youdim MBH and Douce P (eds). Academic Press, pp107-125, 2011. 

15. Bilkei-Gorzo A: The endocannabinoid system in normal and pathological brain ageing. Philosophical Transactions of the Royal Society B: Biological Sciences 367: 3326-3341, 2012. 

16. Germain N, Boichot E, Advenier C, Berdyshev EV and Lagente V: Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells. International immunopharmacology 2: 537-543, 2002. 

17. Marsicano G, Moosmann B, Hermann H, Lutz B and Behl C: Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. Journal of neurochemistry 80: 448-456, 2002. 

18. Esposito G, De Filippis D, Carnuccio R, Izzo AA and Iuvone T: The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. Journal of Molecular Medicine 84: 253-258, 2006. 

19. Esposito G, Filippis DD, Maiuri M, Stefano D and Iuvone T: Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in#2-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-oB involvement. Neuroscience Letters 399: 91-95, 2006. 

20. Harvey BS, Ohlsson KS, Mååg JLV, Musgrave IF and Smid SD: Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. NeuroToxicology 33: 138-146, 2012. 

21. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M and Izzo AA: Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. Journal of neurochemistry 89: 134-141, 2004. 

22. Janefjord E, Mååg JLV, Harvey BS and Smid SD: Cannabinoid Effects on β Amyloid Fibril and Aggregate Formation, Neuronal and Microglial-Activated Neurotoxicity In Vitro. Cellular and Molecular Neurobiology 34: 31-42, 2014. 

23. Martín-Moreno AM, Reigada D, Ramírez BG, et al: Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease. Molecular pharmacology 79: 964-973, 2011. 

24. Scuderi C, Steardo L and Esposito G: Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement. Phytotherapy Research 28: 1007-1013, 2014. 

25. Cheng D, Low JK, Logge W, Garner B and Karl T: Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice. Psychopharmacology 231: 3009-3017, 2014. 

26. Cheng D, Spiro AS, Jenner AM, Garner B and Karl T: Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer's Disease Transgenic Mice. Journal of Alzheimer's Disease 42: 1383-1396, 2014. 

27. Esposito G, Scuderi C, Savani C, et al: Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. Br J Pharmacol 151: 1272-1279, 2007. 

28. Esposito G, Scuderi C, Valenza M, et al: Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement. PLOS ONE 6: e28668, 2011. 

29. Yiannopoulou KG and Papageorgiou SG: Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 6: 19-33, 2013